GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company with a strong pipeline of drugs in oncology, immunology, and cardiovascular diseases. Its share price depends on the success of its key drugs and its ability to expand its pipeline through research and acquisitions.
Share prices of companies in the market segment - Pharma holding
Bristol-Myers Squibb is a global pharmaceutical giant with key segments in oncology, immunology, and cardiology. We classify it as part of the Pharma Holdings sector, and the chart below shows the overall dynamics of the entire large drug manufacturing industry.
Broad Market Index - GURU.Markets
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio of oncology and immunology drugs. Its significant market capitalization earns it a prominent place in the GURU.Markets index. The chart below represents the entire market. See how BMY shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BMY - Daily change in the company's share price Bristol Myers Squibb
The daily price change for Bristol-Myers Squibb, a pharmaceutical giant, is a measure of its reaction to clinical trial results and regulatory announcements. While the graph of these fluctuations is unspectacular, it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
Bristol-Myers Squibb is a leader in the global pharmaceutical industry. This chart reflects the average daily volatility of the entire sector. It serves as a benchmark for comparing the company's robust oncology and immunology portfolio to what extent it compares favorably to the industry.
Daily change in the price of a broad market stock, index - GURU.Markets
Bristol-Myers Squibb is a large biopharmaceutical company specializing in drugs for the treatment of cancer and immune diseases. The pharmaceutical sector may operate by its own rules, but shares of such giants are still subject to overall market trends. The chart below provides context for assessing BMY's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Bristol Myers Squibb
Bristol-Myers Squibb, a major pharmaceutical company, has seen its portfolio of new oncology and immunology drugs grow over the past year, seeking to offset the expiration of patents on older blockbusters. The chart below shows the market's assessment of this renewal strategy.
Annual dynamics of market capitalization of the market segment - Pharma holding
Bristol-Myers Squibb is a major pharmaceutical company whose future depends on the success of its blockbusters, such as Eliquis and Opdivo, and the ability of its R&D division to bring new drugs to market. Its performance chart, compared to the sector, shows how much investors believe in its current portfolio and future potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bristol-Myers Squibb is a large biopharmaceutical company with a strong pipeline of oncology and immunology drugs. Its performance is determined by the life cycle of its blockbusters and research success. A comparison with the market shows how investors assess its ability to offset patent loss with new innovative drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Bristol Myers Squibb
Bristol-Myers Squibb's monthly fluctuations reflect the life cycle of its pharmaceutical blockbusters. The chart's dynamics reflect investor concerns about the impending loss of patent protection for key drugs, while also highlighting hopes for new developments from its R&D pipeline to offset future losses.
Monthly dynamics of market capitalization of the market segment - Pharma holding
This chart shows the dynamics of the entire pharmaceutical sector. For Bristol-Myers, one of the giants, it's the backdrop. It shows how the company, while managing a portfolio of oncology and immunology blockbusters, is seeking new sources of growth through in-house development and major acquisitions.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio of oncology and immunology drugs. Like other pharma giants, it is considered relatively defensive. The chart below shows overall market sentiment, with BMY shares often dependent more on news about its blockbuster drugs than on market panic.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Bristol Myers Squibb
Bristol-Myers Squibb, a major pharmaceutical company, sees its weekly performance dependent on sales news for its blockbusters, such as Eliquis and Opdivo, and the results of clinical trials for new drugs. Investors are closely monitoring how the company handles patent expirations.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Bristol-Myers Squibb, like other large pharmaceutical companies, often follows the mainstream. However, investors compare its product portfolio and R&D success to those of its competitors. The chart shows whether the market is rewarding its successes, such as with Eliquis, with a higher valuation than the industry average, or whether the company is lagging behind.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Bristol-Myers Squibb is a global pharmaceutical company. Like other Big Pharma companies, its shares are often considered "defensive" due to stable demand. The chart will show whether its weekly fluctuations actually smooth out overall market volatility.
Market capitalization of the company, segment and market as a whole
BMY - Market capitalization of the company Bristol Myers Squibb
Bristol-Myers Squibb's market capitalization dynamics tell the story of a major pharmaceutical company that made a bold bet on immuno-oncology with the acquisition of Celgene. The chart shows how investors evaluate the synergies from this deal and its pipeline of leading drugs. The company's valuation depends on its ability to successfully integrate assets and offset the loss of patents on older drugs.
BMY - Share of the company's market capitalization Bristol Myers Squibb within the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with strong market share, particularly in oncology and cardiovascular diseases. Its market capitalization reflects the success of blockbusters like Eliquis and Opdivo and its commitment to scientific innovation.
Market capitalization of the market segment - Pharma holding
Here's a chart showing the trillion-dollar value of the global pharmaceutical industry. Bristol-Myers Squibb is one of its leaders, with strong positions in oncology and immunology. The dynamics of this market are determined by both advances in the development of new drugs and the loss of patent protection for existing ones, forcing companies like BMY to constantly seek innovation.
Market capitalization of all companies included in a broad market index - GURU.Markets
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio of oncology and immunology drugs. Its market capitalization reflects the value of its innovations in treating complex diseases. The chart below shows the weight of big pharma in the market structure.
Book value capitalization of the company, segment and market as a whole
BMY - Book value capitalization of the company Bristol Myers Squibb
Bristol-Myers Squibb's book value is a material foundation built on advanced R&D centers and manufacturing facilities for innovative drugs in oncology and immunology. The chart below is a financial reflection of its strategy, which includes both in-house development and major acquisitions (such as Celgene), which have fundamentally altered its balance sheet.
BMY - Share of the company's book capitalization Bristol Myers Squibb within the market segment - Pharma holding
CVS Health is more than a pharmacy; it's a vertically integrated healthcare giant. The chart shows its massive share of the sector's physical assets. These include thousands of pharmacies, MinuteClinics, and distribution centers that create a unique ecosystem for healthcare delivery.
Market segment balance sheet capitalization - Pharma holding
Bristol-Myers Squibb is an innovative pharmaceutical company. The sector's asset chart confirms its capital intensity. BMS relies on knowledge-intensive capital, investing billions in R&D, but also owns sophisticated manufacturing facilities for its oncology and immunology drugs.
Book value of all companies included in the broad market index - GURU.Markets
Bristol-Myers Squibb is a global biopharmaceutical company with strong positions in oncology and immunology. Its significant book value is the result of the acquisition of Celgene, which brought it not only manufacturing facilities but also a portfolio of blockbuster drugs and promising developments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Bristol Myers Squibb
Bristol-Myers Squibb is a pharmaceutical giant. Its premium reflects the value of its portfolio of oncology and immunology drugs. The chart shows how the market perceives its ability to offset the loss of patents on older drugs with new developments.
Market to book capitalization ratio in a market segment - Pharma holding
Bristol-Myers Squibb is a global pharmaceutical company with strong positions in oncology and immunology. Its valuation depends on the success of its key drugs and its ability to expand its pipeline with new developments. This chart shows how investor expectations regarding its product pipeline shape the premium placed on its significant manufacturing assets.
Market to book capitalization ratio for the market as a whole
Bristol-Myers Squibb is a global biopharmaceutical company specializing in drugs for the treatment of oncology, cardiovascular, and immunological diseases. This chart shows the average market valuation of the business. Against this backdrop, its valuation reflects both the profitability of current blockbusters and investor concerns about patent expirations.
Debts of the company, segment and market as a whole
BMY - Company debts Bristol Myers Squibb
For Bristol-Myers Squibb, the debt history of recent years is defined by the $74 billion mega-acquisition of Celgene, which was largely financed with debt. This chart clearly shows how the company used leverage to become a leader in oncology and radically transform its product portfolio.
Market segment debts - Pharma holding
Bristol-Myers Squibb is a global pharmaceutical company. Its debt profile changed dramatically after the massive acquisition of Celgene, which was financed primarily with debt. Since then, one of management's primary goals has been to reduce its debt burden using cash flows from the combined drug portfolio. This chart illustrates this story.
Market debt in general
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio of oncology and immunology products. The company grew through the large acquisition of Celgene, which significantly increased its debt load. This total debt chart provides important context for assessing how BMS is managing its integration and debt reduction.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Bristol Myers Squibb
Bristol-Myers Squibb is a major pharmaceutical company that has placed significant emphasis on oncology and immunology, including through its mega-acquisition of Celgene. This chart shows the extremely high debt burden incurred as a result of this deal. The company's ability to service this debt depends on the success of the acquired drugs and its own developments.
Market segment debt to market segment book capitalization - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company focused on treating serious diseases such as cancer and cardiovascular disease. The company has grown in part through major acquisitions. This chart shows how these deals have impacted its balance sheet, comparing its debt to the market capitalization of the pharmaceutical industry as a whole.
Debt to book value of all companies in the market
Bristol-Myers Squibb, a major pharmaceutical giant, grew in part through its debt-financed acquisition of Celgene. This chart shows the financial impact of that deal. It compares the company's high debt load to the average level for the economy, reflecting its aggressive growth strategy through M&A.
P/E of the company, segment and market as a whole
P/E - Bristol Myers Squibb
This chart for Bristol-Myers Squibb, a major pharmaceutical company, shows how investors value its drug portfolio. The P/E ratio depends on the sales of its blockbuster oncology and cardiology drugs, as well as the market's perception of the prospects of its scientific developments, which should offset future patent losses.
P/E of the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with strong positions in oncology, immunology, and cardiovascular disease. The company has grown through major acquisitions. This chart shows the average valuation for the pharmaceutical industry, helping investors understand how the market values merger synergies and Bristol-Myers' pipeline.
P/E of the market as a whole
Bristol-Myers Squibb is a global biopharmaceutical company with strong positions in oncology and immunology. Its valuation depends on the success of key drugs such as Eliquis and Opdivo and its ability to expand its portfolio with new developments. As with other large pharmaceutical companies, the general economic cycles visible on the chart are less important than clinical trial news.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on treating serious diseases, particularly in oncology and immunology. This chart reflects investor expectations for its pipeline and R&D. The valuation depends on sales forecasts for blockbusters such as Eliquis and Opdivo and the success of new drugs entering the market.
%20P%2FE%20Bristol%20Myers%20Squibb&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Bristol-Myers-Squibb&v=1772642666563 "Chart of the company's future (projected) P/E Bristol Myers Squibb")
Future (projected) P/E of the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with a strong pipeline of oncology and immunology drugs. This chart reflects the market's assessment of its scientific developments and future revenue. Comparing its profit forecasts with the sector reveals how confident investors are in its ability to offset the loss of patents on older drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772642666567 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Bristol-Myers Squibb is a global biopharmaceutical company with strong positions in oncology and immunology. Its future depends on the successful launch of new drugs and the integration of acquired assets. The overall market backdrop, as shown in this chart, influences the sector's valuation, but for BMS, clinical trial data is key.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772642666598 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Bristol Myers Squibb
Bristol-Myers Squibb Company is a global biopharmaceutical company focused on treating serious diseases such as cancer and cardiovascular disease. Its profits depend on sales of key drugs, such as Eliquis and Opdivo, and on the success of its new drug development efforts. This chart depicts the life cycle of its pharmaceutical portfolio.
Profit of companies in the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio of drugs in oncology, immunology, and cardiovascular diseases. The company is actively expanding through strategic acquisitions. Its success in developing and commercializing new drugs is a significant driver of overall profitability and innovation in the pharmaceutical industry.
Overall market profit
Bristol-Myers Squibb is a global biopharmaceutical company specializing in the development of innovative medicines for the treatment of serious diseases, primarily cancer, cardiovascular, and immunological disorders. The success of its blockbuster oncology drugs makes the company a leader in this critically important area of medicine and contributes significantly to the sector's profitability.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio in oncology and immunology. This chart reflects expectations for sales of its key drugs, such as Eliquis and Opdivo, and the company's ability to replenish its R&D pipeline to offset future patent gaps.
%20profit%20of%20the%20company%20Bristol%20Myers%20Squibb&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Bristol-Myers-Squibb&v=1772642666657 "Graph of future (projected) profit of the company Bristol Myers Squibb")
Future (predicted) profit of companies in the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with a strong portfolio in oncology, immunology, and cardiovascular diseases. The data in the chart shows profit forecasts for the entire pharmaceutical industry. This allows us to assess how the company is coping with patent losses on key drugs and developing new products.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772642666668 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
This chart shows expectations for a major biopharmaceutical company. Bristol-Myers Squibb's profit outlook depends on sales of its blockbuster oncology and immunology drugs. Successful integration of acquired companies, such as Celgene, and the ability to offset patent losses with new drugs determine long-term growth.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772642666683 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company with strong positions in oncology and immunology. This chart shows how investors value its revenue given the upcoming loss of patent protection for its key drugs. The multiple reflects the balance between current sales and the uncertainty of future growth.
P/S market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with a strong pipeline of drugs in oncology, immunology, and cardiovascular diseases. This chart shows the average revenue estimate in the pharmaceutical industry. It helps assess how investors perceive the company's product portfolio after major mergers and the risk of patent expiration.
P/S of the market as a whole
Bristol-Myers Squibb is a global biopharmaceutical company with a strong pipeline of oncology and immunology drugs. Its revenue depends on the success of its key drugs and the ability to expand its pipeline with new ones. This chart, showing the average revenue estimate for BMY, helps understand how the market views its pipeline and the upcoming patent collapses.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company with a strong pipeline of oncology and immunology drugs. Future revenue depends on sales of blockbusters like Eliquis and Opdivo, as well as the success of new developments. This chart shows how investors assess its ability to offset the loss of patent protection on key drugs in the future.
%20P%2FS%20Bristol%20Myers%20Squibb&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Bristol-Myers-Squibb&v=1772642666842 "The graph of the company's future (projected) P/S Bristol Myers Squibb")
Future (projected) P/S of the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with strong positions in oncology and immunology. This chart shows how the market views its product portfolio and prospects. Do investors believe its new drugs will be able to offset the upcoming patent loss on key drugs like Eliquis and Opdivo?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772642666855 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Bristol-Myers Squibb is a global biopharmaceutical company with strong positions in oncology and immunology. Its revenue depends on the success of its key drugs and its ability to bring new ones to market. BMS's research progress and commercial success support overall positive expectations for the healthcare sector, as illustrated by this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772642666881 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on developing medicines to treat serious diseases in areas such as oncology, immunology, and cardiology. This chart shows the commercial success of its key drugs, such as Eliquis and Opdivo, in the global market.
Sales of companies in the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with a strong pipeline of drugs in oncology, immunology, and cardiovascular diseases. Its growth is based on successful development and strategic acquisitions. This chart shows overall pharmaceutical sales, highlighting the competitive landscape in which BMY strives for leadership in its key niches.
Overall market sales
Bristol-Myers Squibb is a global biopharmaceutical company focused on developing innovative medicines in areas such as oncology, immunology, and cardiovascular diseases. This overall economic activity graph is indirectly important for BMS, as it impacts healthcare funding and the availability of its drugs to patients worldwide.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on developing drugs to treat serious diseases, primarily cancer. Future revenue depends on sales of its key drugs, such as Eliquis and Opdivo, and the success of its R&D. This chart shows how analysts assess the life cycles of current blockbusters and the potential of new drugs.
%20sales%20of%20the%20company%20Bristol%20Myers%20Squibb&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Bristol-Myers-Squibb&v=1772642666911 "Schedule of future (projected) sales of the company Bristol Myers Squibb")
Future (projected) sales of companies in the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company specializing in drugs for the treatment of oncology, cardiovascular, and immunological diseases. This chart shows projected revenues for the entire pharmaceutical sector. It provides insight into overall trends, which is important context for evaluating BMS's blockbuster portfolio.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772642666915 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Bristol-Myers Squibb is a global biopharmaceutical company specializing in drugs for the treatment of oncology, cardiovascular, and immunological diseases. Demand for its products is high and inelastic. However, this chart is important for assessing the ability of healthcare systems worldwide, particularly public ones, to finance the expensive, innovative treatments offered by the company.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772642666921 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company specializing in the treatment of oncology, cardiovascular, and immunological diseases. This chart shows financial results, which depend on the success of its key blockbuster drugs. The dynamics reflect the drug life cycle and the success of acquisitions, such as the purchase of Celgene.
Market segment marginality - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company with a strong pipeline of drugs in oncology, immunology, and cardiovascular diseases. The success of blockbusters like Eliquis and Opdivo is a key driver of its financial results. This metric demonstrates how innovative, proprietary drugs generate profitability above the industry average.
Market marginality as a whole
Bristol-Myers Squibb is a global biopharmaceutical company specializing in innovative oncology and immunology drugs. This chart shows overall profit margins. Against this backdrop, BMS demonstrates how successful acquisitions (such as Celgene) and a blockbuster pipeline can support the high profitability needed to fund expensive research.
Employees in the company, segment and market as a whole
Number of employees in the company Bristol Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company with a strong pipeline of drugs in oncology, immunology, and cardiovascular diseases. This chart shows the company's scale following major acquisitions, such as Celgene. The growth in headcount reflects the company's strategy to strengthen its pipeline of innovative drugs and R&D pipeline.
Share of the company's employees Bristol Myers Squibb within the market segment - Pharma holding
This figure demonstrates Bristol-Myers Squibb's importance as one of the world's leading producers of innovative medicines. A significant portion of its pharmaceutical workforce is focused on developing drugs in key areas such as oncology, immunology, and cardiovascular diseases. This represents the scientific and commercial potential behind breakthrough treatments.
Number of employees in the market segment - Pharma holding
Bristol-Myers Squibb is a global biopharmaceutical company focused on treating serious diseases, particularly in oncology and immunology. The company's success depends on its ability to deliver scientific breakthroughs. This chart illustrates the high demands placed on scientific talent in the modern pharmaceutical industry, where BMS is a leader in R&D.
Number of employees in the market as a whole
Bristol-Myers Squibb (BMY) is a large pharmaceutical company with a strong focus on oncology (Opdivo, Revlimid) and immunology. They specialize in treating complex diseases. This graph of total employment shows the state of payers. BMY's success depends on the ability of the healthcare system, financed by employee contributions, to pay for their expensive and innovative drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Bristol Myers Squibb (BMY)
Bristol-Myers Squibb is a global biopharmaceutical company focused on treating serious diseases such as cancer. Its high market capitalization per employee directly reflects the value of its proprietary drug portfolio and its R&D capabilities.
%20of%20the%20company%20Bristol%20Myers%20Squibb%20(BMY)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Bristol-Myers-Squibb-BMY&v=1772642666948 "Chart of market capitalization per employee (in thousands of dollars) of the company Bristol Myers Squibb (BMY)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Bristol-Myers Squibb (BMY) is a large pharmaceutical company whose value, like that of its competitors, is determined by its R&D pipeline (especially in oncology). This chart shows the market capitalization per employee, which is a barometer of the market's confidence in the productivity of its scientific research and future blockbusters.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772642666949 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Bristol-Myers Squibb is a global biopharmaceutical company focused on oncology, immunology, and cardiovascular diseases. This chart shows a high salary per employee, which is the industry norm. The company's value is determined by its proprietary drug portfolio and the success of its R&D.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772642666950 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Bristol Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) is a major pharmaceutical giant that became a leader in oncology (Opdivo) and cardiology (Eliquis) after acquiring Celgene. This chart shows how successful this focus on R&D has been. The success of these blockbusters ensures the company's high profitability and recoups the billions spent on research and M&A.
%20Chart%20Bristol%20Myers%20Squibb%20(BMY)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Bristol-Myers-Squibb-BMY&v=1772642666951 "Company Profit Per Employee (in thousands of dollars) Chart Bristol Myers Squibb (BMY)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Bristol-Myers Squibb (BMY) is a major pharmaceutical giant. This chart shows the industry average for the entire pharmaceutical industry. This sector is a "blockbuster business." Average employee profitability is high, as a single successful drug patent (like Eliquis) can generate billions, recouping all R&D costs and providing high profits per scientist.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772642666953 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Bristol-Myers Squibb is a global biopharmaceutical company specializing in the treatment of oncology, cardiovascular, and immunological diseases. The company is rapidly growing through acquisitions and the development of innovative drugs. This chart shows how successful R&D and strategic M&A transactions impact profitability per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772642666955 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Bristol Myers Squibb (BMY)
Bristol-Myers Squibb is a global biopharmaceutical company focused on treating serious diseases, particularly oncology. This chart illustrates how successful proprietary drugs like Opdivo and Eliquis generate billions of dollars in revenue while delivering superior productivity per employee.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Bristol-Myers-Squibb-BMY&v=1772642666968 "Sales chart per company employee Bristol Myers Squibb (BMY)")
Sales per employee in the market segment - Pharma holding
Bristol-Myers Squibb (BMS) is a global pharmaceutical company with strengths in oncology and immunology, particularly after acquiring Celgene. This chart shows the average revenue per employee in the segment. It helps assess how productive their combined R&D and commercial teams are in advancing their blockbuster pipeline compared to competitors.
Sales per employee for the market as a whole
Bristol-Myers Squibb (BMY) is a major pharmaceutical company that gained strength after acquiring Celgene, giving them a strong portfolio in oncology (Revlimid) and immunology (Eliquis). Like Merck, their business is characterized by blockbusters. This chart shows how their key proprietary drugs generate billions of dollars in revenue, providing a high return on investment.
Short shares by company, segment and market as a whole
Shares shorted by company Bristol Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) is a pharmaceutical company with strengths in oncology and immunology. The bearish sentiment seen on this chart is linked to the looming patent cliff. Key drugs (Eliquis, Opdivo) will soon face generic competition, and bears doubt BMY's new developments will be able to offset this.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Bristol-Myers-Squibb-BMY&v=1772642666994 "Short Shares Chart for the Company Bristol Myers Squibb (BMY)")
Shares shorted by market segment - Pharma holding
Bristol-Myers Squibb (BMY) is a large pharmaceutical company that became a giant after acquiring Celgene, with strong positions in oncology (Opdivo) and cardiology (Eliquis). This chart shows the overall sentiment around the sector. It reflects investor concerns about "patent cliffs" (loss of exclusivity) for key drugs across the pharmaceutical industry.
Shares shorted by the overall market
Bristol-Myers Squibb is a global pharmaceutical company specializing in innovative treatments for cancer and immune diseases. Demand for its lifesaving drugs is unaffected by economic cycles. This chart shows the overall level of pessimism. When it rises, BMY often serves as a safe haven for investors seeking protection from market turbulence.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Bristol Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) is a pharmaceutical giant facing a "patent cliff" (loss of protection) for key blockbusters (Eliquis, Opdivo). This chart measures momentum. "Oversold" (below 30) indicates panic. Investors fear the company's R&D portfolio is too weak to replace lost revenue. "Overbought" (above 70) indicates the market has become convinced of the success of new drugs or a successful M&A.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Bristol-Myers-Squibb-BMY&v=1772642667009 "RSI 14 indicator chart for the company's stock Bristol Myers Squibb (BMY)")
RSI 14 Market Segment - Pharma holding
Bristol-Myers Squibb (BMY) is a major player in Big Pharma, with a strong presence in oncology (Opdivo). The company is facing a "patent collapse" on key drugs. This metric measures the overall momentum of the sector. It helps understand whether BMY is oversold due to its unique patent risks, or whether Big Pharma as a whole is in a "cooling down" phase due to regulatory pressure.
RSI 14 for the overall market
Bristol-Myers Squibb (BMY) is a biopharmaceutical giant focused on breakthrough treatments for cancer and immune diseases. Their success depends on clinical trial results, not market sentiment. This chart shows investor sentiment, but patients need BMY's drugs in both euphoria and panic. This makes the company's shares relatively defensive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BMY (Bristol Myers Squibb)
The average price target on this chart is an estimate of how Bristol-Myers Squibb will cope with the "patent cliff." When making their forecasts, analysts weigh the decline of old blockbusters (Eliquis) against the potential of new drugs (Opdualag). Consensus represents the belief (or doubt) that the company's R&D pipeline will be able to compensate for the losses.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BMY-Bristol-Myers-Squibb&v=1772642667013 "A chart showing analyst consensus forecasts for the expected stock price. BMY (Bristol Myers Squibb)")
The difference between the consensus estimate and the actual stock price BMY (Bristol Myers Squibb)
Bristol-Myers Squibb is a large biopharmaceutical company with strengths in oncology (Opdivo) and cardiology (Eliquis). Their challenge is the patent cliff and loss of exclusivity on key drugs. This chart shows analysts' confidence in their new pipeline and recent M&A. It reflects the gap between the consensus estimate and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BMY-Bristol-Myers-Squibb&v=1772642667031 "A chart showing the difference between the consensus forecast and the actual stock price. BMY (Bristol Myers Squibb)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Bristol-Myers Squibb (BMY) is a large pharmaceutical company with strengths in oncology (Opdivo) and cardiovascular treatment (Eliquis). This chart shows the analyst consensus forecast for all of Big Pharma. It reflects whether experts believe new drugs in the industry will offset the expiration of old patents.
Analysts' consensus forecast for the overall market share price
Bristol-Myers Squibb (BMY) is a global big pharma company with a strong portfolio in oncology and immunology. Like other pharmaceutical companies, BMY is considered a defensive sector. However, the overall market sentiment chart influences the company. During periods of optimism, investors may value BMY lower than hot biotechs, but in times of crisis, they value its stable cash flow.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Bristol Myers Squibb
Bristol-Myers Squibb (BMY) is a large pharmaceutical company that became a giant after acquiring Celgene. Their strength lies in oncology (Opdivo) and cardiovascular drugs (Eliquis). This chart reflects the perpetual race in pharma: it weighs revenue from current blockbusters against the inevitable patent cliff (loss of exclusivity for Revlimid) and hopes for a new R&D pipeline.
AKIMA Market Segment Index - Pharma holding
Bristol-Myers Squibb is a major pharmaceutical company that has become a leader in immuno-oncology (Opdivo) and cardiovascular disease treatment (Eliquis). This comprehensive index evaluates R&D. The chart shows the average value for the segment. This benchmark: how strong is BMS's blockbuster portfolio and R&D pipeline, distinguishing it from the average pharmaceutical company?
The AKIM Index for the overall market
Bristol-Myers Squibb (BMY) is a large biopharmaceutical company focused on oncology, immunology, and cardiovascular diseases. The company is actively working to replace revenue from aging patents. This chart, which reflects the market average, provides a macro backdrop. It helps assess how BMY, which is addressing its own internal R&D needs, compares to the broader economic trends that influence investor sentiment in the healthcare sector.
